Region · 92 analyses
In the UK a single national appraisal decides commissioning, and the route it takes — standard appraisal or the ultra-rare pathway — sets the cost-effectiveness bar an asset must clear.
NICE is the gate. A positive technology appraisal triggers a mandatory funding obligation in England, so a recommendation converts to commissioned access in a way few other markets match. A rejection leaves an asset without a route, whatever the licence says.
Which pathway an appraisal takes matters more than most launch plans assume. The standard Technology Appraisal route applies an ordinary cost-per-QALY threshold; the Highly Specialised Technologies route applies a far higher one, but admits very few medicines. Assuming the ultra-rare route and being assessed on the standard one is the single most expensive planning error in UK rare disease, and the AXLRx corpus documents several therapy areas where every incumbent cleared the standard bar — setting a precedent a new entrant inherits whether or not it wants to.
Almost every recommendation is underpinned by a confidential commercial arrangement, so published list prices reveal little about what the NHS actually pays. Scotland and Wales assess separately, and can and do diverge.
AXLRx UK reports work that structure directly: which route an asset should expect, the precedent set by agents already through, the discount implied to clear the threshold, and the evidence a submission has to be built on from the first dossier decision.